ReviewExperimental and therapeutic medicine2025
Exploring the interactions of integrins and CEACAM6 (Review).
Review in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Progress in the application ofAnnals of nuclear medicine · 2026Review
- Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types, and is characterized by rapid progression, resistance to therapy and poor overall prognosis. Adhesion molecules can influence signal transduction, survival, pathogenesis, development and progression in PDAC. However, the role of adhesion molecules and therapeutic targets in PDAC is inadequately characterized. Therefore, the present review critically evaluated the interactions, associations and co-expression patterns of adhesion molecules in PDAC. The interaction between adhesion molecules, such as carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) and integrins, can influence the differentiation, activation, proliferation, metastasis and cytoskeletal remodeling of cancer cells. In addition, adhesion molecules can regulate tumor progression, metastasis, and cellular adhesion and signaling. The present analysis has brought to attention the interaction between CEACAM6 and integrins, which may affect the prognosis of PDAC. Functional and molecular evaluation revealed that CEACAM6 contributes to resistance to anoikis in PDAC through interactions with partner proteins and activation of survival signaling pathways, particularly the Src/focal adhesion kinase axis. In conclusion, the interaction between CEACAM6 and integrins can influence PDAC progression, desmoplasia and treatment resistance. Targeting this adhesion signaling axis presents a promising strategy to improve diagnostic precision and develop more effective personalized therapies for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.